<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879007</url>
  </required_header>
  <id_info>
    <org_study_id>LG-AACL006</org_study_id>
    <nct_id>NCT01879007</nct_id>
  </id_info>
  <brief_title>Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)</brief_title>
  <official_title>Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      This study seeks to compare the pharmacokinetic characteristics of Factive 200mg Intravenous
      Formulation (Gemifloxacin 200mg) with those of Factive 320mg Tablet Formulation (Gemifloxacin
      320mg) and to explore possibility of clinical use of the IV formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vss</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>F</measure>
    <time_frame>Up to 48 hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Infectious Diseases</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received one intravenous administration and one oral medication with interval of 1 week,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received one oral administration and one intravenous medication with interval of 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FactiveÂ® Tab / Factive IV</intervention_name>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Korean males between 19 and 45 years of age, weighing within 15% deviation of
             the ideal weight (CRC criteria) and residing in Korea (Appendix 4)

          2. Applicants judged eligible as subject based on health exams (interview, blood
             pressure, 12-lead ECG, physical exam, blood and urine tests, and other screening
             tests) conducted not more than three weeks prior to administration (those with two or
             less clinically significant results)

          3. Applicants who can take part in the whole process of clinical study

          4. Applicants who sufficiently received explanation on the purpose and content of
             clinical study, characteristics of the investigational products, etc., before
             participating in the study and gave written consent to participate in the study
             voluntarily

        Exclusion Criteria:

          1. Applicants who exhibit symptoms suspected to be those of acute diseases prior to the
             start of the study

          2. Clinically significant kidney disease or liver disease

          3. Cardiovascular, respiratory, renal, endocrine system, hematology (hemorrhagic
             diathresis), digestive system (peptic ulcer), central nerve system, psychiatric
             disorder, or malignant tumors; chronic diseases that can influence the absorption,
             distribution, metabolism, or excretion of drugs

          4. Applicants who have been on an abnormal diet, which can influence the absorption,
             distribution, metabolism, or excretion of drugs

          5. Medical history of gastrointestinal resection except appendectomy

          6. Applicants testing positive for hepatitis B antigen, hepatitis C antibody, or HIV
             antibody;

          7. Clinically significant allergic diseases (excluding mild allergic rhinitis that does
             not require medication)

          8. Known history of hypersensitivity to drugs

          9. Known history of developing complications such as epilepsy or other convulsive
             diseases

         10. Excessive consumption of caffeine and alcohol or heavy smoker

         11. History of alcohol or drug abuse

         12. Applicants who cannot take the standard meals provided by ASAN Medical Center(AMC)

         13. Donation of whole or apheresis blood prior to the administration

         14. Participation in other clinical study as subjects prior to the administration

         15. Applicants who have taken prescription drugs prior to the administration or
             OTC(over-the-counter) drugs prior to the administration and for which such medications
             are judged by the principal investigator to have an influence on this study or on the
             safety of the subject

         16. Applicants who are highly likely to take other medication during the study

         17. Applicants who took medication that induces or inhibits drug-metabolizing enzymes such
             as barbiturates or consumed excessive amounts of alcohol less than 1 month prior to
             the administration

         18. Medical history of meningitis, encephalitis, or brain injury

         19. Difficulty in cooperating with researchers in proceeding with the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

